CTNNB1 Foundation: Clinical Trials

2 trials sponsored by CTNNB1 Foundation, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Recruiting 1
Phase 21Recruiting 1

Follow CTNNB1 Foundation: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome
Urbagen gene addition therapy, Sirolimus, Methylprednisolone (Corticosteroid) - CTNNB1 Neurodevelopmental Syndrome
Phase 1 / Phase 2RecruitingCTNNB1 Foundation122025-11-012026-03-25
CTNNB1 Neurodevelopmental Syndrome - Natural History Study
A General Medical and Neurological Assessment, World Health Organisation (WHO) Motor Milestones, Burke-Fahn-Marsden Dystonia Rating Scale - CTNNB1 Neurodevelopmental Syndrome
RecruitingUniversity Medical Centre Ljubljana2502024-06-142025-09-22

Conditions studied

Autism Spectrum Disorder (1)  ·  Learning Disabilities (1)

Interventions

Adrenal Cortex Hormones (1)  ·  Methylprednisolone (1)  ·  Neurologic Examination (1)  ·  Sirolimus (1)  ·  Tomography, Optical Coherence (1)

Countries

Slovenia (2)  ·  Australia (1)

NIH funding

2025 (1)